Inhibition of IL-17A in atherosclerosis
X Cheng, S Taleb, J Wang, TT Tang, J Chen, XL Gao… - Atherosclerosis, 2011 - Elsevier
OBJECTIVE: To determine the effects of interleukin (IL)-17A inhibition on experimental
atherosclerosis. METHODS AND RESULTS: ApoE−/− mice were treated with either rat anti-
mouse IL-17A, mouse anti-mouse IL-17A or isotype-matched control antibodies for 12
weeks (n= 8–10 per group). Ldlr−/− mice were transplanted with IL-17A-deficient or wild type
bone marrow (n= 8 per group). Rat anti-mouse IL-17A treatment obviously reduced plaque
size by 43%(p< 0.01) without evidence of reduced IL-17A signaling. In contrast, mouse anti …
atherosclerosis. METHODS AND RESULTS: ApoE−/− mice were treated with either rat anti-
mouse IL-17A, mouse anti-mouse IL-17A or isotype-matched control antibodies for 12
weeks (n= 8–10 per group). Ldlr−/− mice were transplanted with IL-17A-deficient or wild type
bone marrow (n= 8 per group). Rat anti-mouse IL-17A treatment obviously reduced plaque
size by 43%(p< 0.01) without evidence of reduced IL-17A signaling. In contrast, mouse anti …
